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pneumonitis. Patients with minimum grade 2 were considered 
as RP. 
 
Results: Composite perfusion changes were associated with 
dose. Statistically significant dose-dependent reduction in 
regional perfusion was observed at 3, 6 and 12 months FU. 
Comparison of dose-response curves based on their slopes 
showed a dose-dependent reduction in perfusion at all time 
intervals (R2=0.8-0.9) except 1 month (R2=0.4). Relative 
perfusion loss per dose bin was 4% at 1 month, 14% at 3 
months, 13% at 6 months and 21% at 12 months FU (Figure 1).  
 
The dose-response relations varied between patients with or 
without RP. In patients who developed RP, perfusion 
reduction was larger in 20-40 Gy dose bin at 3 months FU 
(p=0.04), and in >60 Gy dose bin at 6 months (p=0.03), 
compared to those without the complication. Low dose 
regions, on the contrary, revealed larger perfusion increase 
at 12 months FU in the patients with RP (p=0.002). 
 
Conclusion: Progressive dose dependent perfusion loss was 
seen on SPECT up to 12 months following IMRT. Patients with 
radiation pneumonitis demonstrate a larger perfusion loss in 
the high dose regions, as well as relatively larger perfusion 
increase in regions receiving low dose, possibly due to 
function being shunted to these areas. 
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Purpose or Objective: There are several potentially 
radioresistant targets for dose escalation in dose-painting 
apporoach. Among them tumor hypoxia is a very attractive 
target. However, 2-3 times higher radiation dose is required 
to overcome hypoxia-mediated radioresistance in tumors, 
which is clinically difficult to achieve due to normal tissues 
constraints. Therefore, we propose a novel treatment 
approach to combine 1) targeting hypoxic tumor cells with a 
hypoxia-activated prodrug (HAP) TH302 and 2) at the same 
time use inverse radiation dose-painting strategy to boost 
tumor subvolumes with no/low drug uptake. We tested this 
approach in a rat rhabdomyosarcoma model using 18F-HX4 
hypoxia tracer, which is a surrogate of TH302 accumulation in 
a tumor. 
 
Material and Methods: A clinical PET/CT scanner was used to 
evaluate 18F-HX4 uptake 3 hrs post injection. Low or high 
drug uptake volume (LDUV or HDUV) was defined as 40% of 
the GTV with the highest or the lowest 18F-HX4 uptake, i.e. 
TH302 accumulation. Within 24 hrs after PET/CT animals 
(n=9) received either a single dose radiotherapy (RT) 
uniformly or a dose-painted non-uniform irradiation with 50% 
higher dose to LDUV or to HDUV. Mean dose in uniform RT 
was 18.5 Gy similarly to the mean dose in DUV. Mean dose to 
the GTV in the non-uniform RT scenario was 14.9 Gy. 
Treatment plans were created using Eclipse treatment 
planning system. Animals were irradiated on a TrueBeam 
High Definition 120 Leaf MLC linac. Tumor response was 
quantified as time required to reach 3-times starting tumor 
volume (TGTV3). 
 
Results: Non-uniform RT with radiation boost to tumor 
subvolumes with low TH302 uptake (LDUV) was much more 
effective than the same dose escalation to subvolumes with 
high drug uptake (Fig. 1). Noteworthy, dose escalation to 
LDUV was as effective as uniform RT with 3.6 Gy higher mean 
dose to GTV. 
 
Fig. 1.Time to reach 3-times starting tumor volume (TGTV3) 
after uniform RT or non-uniform RT with dose escalation to 
tumor volume with high drug uptake (HDUV) or low drug 
uptake (LDUV). Mean dose (Dm) to GTV is indicated. 
 
Conclusion: The results of this pilot study support targeted 
dose escalation in non-hypoxic tumor subvolumes with 
no/low accumulation of hypoxia-activated prodrugs, which 
requires further confirmation. This strategy appears to be as 
effective as a uniform dose escalation of the entire GTV but 
with greater capacity to spare normal tissues. It is expected 
that this approach of inverse dose-painting can be combined 
with other imageable cytotoxic drugs, which warrants further 
investigations. 
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The implicit concept behind the title of this lecture concerns 
the role of “quantitative” data-driven approaches in 
assessing dose-volume effects in normal tissues in the era of 
“high-tech” radiotherapy and integration of “omics”. The 
continuously growing literature regarding dose-volume 
relationships indirectly reflects the need of improving and 
refining our knowledge in this field [1]. This seems to be 
particularly urgent in a number of clinically relevant 
situations such as, for instance, heart, bowel and bladder. 
However, the impact of the above mentioned elements 
(“high-tech & “omics”) on the research issues of this field is 
increasingly relevant and claims for the development of new 
research lines and methods that will shortly be overviewed in 
the lecture.  
